An interventional study of Accuboost APBI in Breast Cancer, sponsored by Brown University. Completed at 3 sites in United States. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-03-04.
Sponsored by Brown University · Not applicable, Interventional, and Treatment
To evaluate safety of 5 fraction accelerated partial brest irradiation in more convenient 5 fraction schedule.
The purpose of this study is to evaluate the rate of early and intermediate toxicity related to accelerated partial breast irradiation (APBI) delivered in a more convenient 5 fraction schedule using non-invasive image-guided breast brachytherapy (NIBB) (AccuBoost System) in women with resected, early stage breast cancer.
Non-invasive image-guided breast brachytherapy (NIBB), using advanced image-guided radiation technology, has the potential to eliminate the disadvantages of the conventional APBI techniques. NIBB facilitates non-invasive partial breast irradiation without the use of catheters or implants. Yet by using breast immobilization and precise image-guidance, it reduces non-target breast tissue within the irradiated field compared with other non-invasive APBI techniques such as 3D-CRT. This has made NIBB an attractive approach to deliver APBI.
We hypothesize that NIBB delivered in 5 treatments will be a more convenient, safe and effective modality to deliver partial breast irradiation.
Anticipated advantages of NIBB protocol treatment include:
Brown University is the lead sponsor of 282 studies on the registry; 42 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Pathologic lymph node negative, which includes (pN0 i-, i+);
Patients, who are at very low risk for sentinel node involvement and sentinel node biopsy is not performed, are eligible if the treating investigator documents clinically lymph node negative (cN0). These patients include:
Pathologic tumor size
Exclusion Criteria:
28Gy delivered in 5 daily fractions
Device: Accuboost APBI
28Gy delivered in 5 daily fractions
Number of Patients With Any Toxicity Related to the Radiation Treatment
Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
Time frame: during treatment, 2 and 6 weeks post treatment and then every 6 months for up to 2 years
Number of Participants With Ipsilateral Breast Local Recurrence
Time frame: annually for 2 years post treatment
| Milestone | Accuboost APBI |
|---|---|
| Started | 40 |
| Completed | 40 |
| Not completed | 0 |
Any toxicity related to the radiation treatment will be scored and graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
| Participants | Accuboost APBI |
|---|---|
| Number of Patients With Any Toxicity Related to the Radiation Treatment | 40 |
| Participants | Accuboost APBI |
|---|---|
| Number of Participants With Ipsilateral Breast Local Recurrence | 2 |
Collected over Data was collected from signing of ICF until 5 years post treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Accuboost APBI | — | 0/40 (0%) | 36/40 (90%) |
| Event | Accuboost APBI |
|---|---|
| Acute Skin ReactionSkin and subcutaneous tissue disorders | 32/40 |
| DiscomfortGeneral disorders | 27/40 |
| FatigueGeneral disorders | 19/40 |
| TelangiectasiaSkin and subcutaneous tissue disorders | 13/40 |
| Breast Volume/HypoplasiaReproductive system and breast disorders | 11/40 |
| Skin Induration/FibrosisSkin and subcutaneous tissue disorders | 8/40 |
| HyperpigmentationSkin and subcutaneous tissue disorders | 7/40 |
| Breast PainReproductive system and breast disorders | 5/40 |
| Fibrosis-cosmesisMusculoskeletal and connective tissue disorders | 3/40 |
| Skin AtrophySkin and subcutaneous tissue disorders | 3/40 |
| Age, Categorical(Participants) | Accuboost APBI |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 14 |
| >=65 years | 26 |
| Age, Continuous(years) | Accuboost APBI |
|---|---|
| Mean | 67.45 (50 to 89) |
| Sex: Female, Male(Participants) | Accuboost APBI |
|---|---|
| Female | 40 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Accuboost APBI |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 40 |
| Race (NIH/OMB)(Participants) | Accuboost APBI |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 39 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Accuboost APBI |
|---|---|
| United States | 40 |
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brown University